NHS

Three Questions: Norman Goldfarb, MAGI

Monday, May 15, 2017

CWWeekly presents this biweekly feature as a spotlight on issues that executives in clinical research face. This week, writer Suz Redfearn spoke with Norman Goldfarb, chairman of Model Agreements & Guidelines International (MAGI), an organization that has spent a decade promoting the standardization of clinical trial agreements (CTAs) and contract templates that both sites and CROs or sponsors can use to speed study startup. Goldfarb is also editor of The Journal of Clinical Research Best Practices, and managing director of First Clinical Research. In April, the Association of Clinical Research Professionals gave Goldfarb their award for innovation for the MAGI CTA initiative.

[Read More]

MRC Technology Centre relocates to expand diagnostics research capability

Tuesday, January 17, 2017

MRC Technology, an independent medical research charity, has announced the relocation of its Centre for Diagnostics Development (CDD) to Nine, Edinburgh BioQuarter, in the U.K. The move forms part of the charity’s investment of over £7 million over the next five years to further its work accelerating diagnostic research into the clinic. CDD will potentially double its headcount over the same period.

[Read More]

Report: Clinical research benefits the U.K. economy

Friday, December 2, 2016

An independent report, commissioned by the National Institute for Health Research (NIHR) Clinical Research Network and produced by KPMG’s Economics team, provides an assessment of the economic impact of the NIHR Clinical Research Network’s activities to support clinical research in the U.K. The report includes assessment of the economic contribution made to the U.K. economy through clinical research activity supported by the network; analysis to quantify the value of payments made to NHS Trusts for commercial studies, and the value to the NHS of pharmaceuticals used as part of industry-sponsored studies.

[Read More]

Metrion Biosciences joins human pain research consortium

Monday, August 29, 2016

Metrion Biosciences, a specialist ion-channel and drug discovery CRO, has entered into an agreement with a network of partners to evaluate the use of primary human dorsal root ganglion (hDRG) neurons in pain research. This Consortium comprises the University of Glasgow, the University of St. Andrews, NHS Greater Glasgow & Clyde (NHS-GGC), Metrion Biosciences, the Grünenthal Group in Germany, and the U.K. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), with vital support and facilitation by NHS Blood & Transplant (Scotland). 

[Read More]

Orchard Therapeutics launches, partners on transformative gene therapies

Monday, May 9, 2016

Orchard Therapeutics, a clinical-stage biotechnology company with operations in London and the U.S., has officially launched with a £21-million Series A financing led by F-Prime Capital. As part of its launch, the company has announced formal partnerships with University College London (UCL), Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), the University of Manchester, the University of California Los Angeles (UCLA) and Boston Children’s Hospital for the development of transformative gene therapies for serious and life-threatening orphan diseases.

[Read More]

Upcoming EU referendum delays UK pharma market changes

Monday, April 18, 2016

Civil servants must observe a period of “purdah” in the weeks before a general election or referendum, which restricts government activity to avoid unfairly influencing public opinion. This has hit two major consultations for the pharma industry—the Accelerated Access Review (AAR) and proposed changes to the medicines pricing system known as the Statutory Scheme. The AAR is the brainchild of life sciences minister George Freeman, who wants it to re-shape the U.K. market and the National Health Service (NHS) around encouraging medical innovation, and remove some of the blocks and bottlenecks which plague the current system.

[Read More]